Trends in the Treatment of Hepatocellular Carcinoma

Title: Trends in the Treatment of Hepatocellular Carcinoma

Volume: 5 Issue: 2

Author(s): Janine M. Davies and Bert H. O'Neil

Affiliation:

Keywords: Hepatocellular carcinoma, sorafenib, multikinase inhibitor, treatment

Abstract: HepatoCellular Carcinoma (HCC) is the fifth most common cancer and the third most common cause of cancer- related deaths. In unresectable disease, chemotherapy has modest response rates without a clear improvement in overall survival. Sorafenib is a multikinase inhibitor that recently demonstrated improved overall survival in two randomized clinical trials. This review paper outlines the basic treatment options for HCC by stage, followed by a discussion of key issues in the treatment and management of patients with HCC: the use of targeted therapies and/or chemotherapy in metastatic disease and in different ethnic groups; the potential use of combination therapies in earlier disease stages; and the role of imaging in the era of targeted therapy and the associated challenges.

Cite this article as:

M. Davies Janine and H. O'Neil Bert, Trends in the Treatment of Hepatocellular Carcinoma, Current Drug Therapy 2010; 5 (2) . https://dx.doi.org/10.2174/157488510791065111